Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

ClinicalTrials.gov ID: NCT06411899

Public ClinicalTrials.gov record NCT06411899. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 12:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.

Study identification

NCT ID
NCT06411899
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Enrollment
422 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 15, 2024 (Actual)
Primary completion
Sep 2, 2025 (Actual)
Completion
May 14, 2026 (Actual)
Last update posted
Aug 12, 2026

2024 – 2026

United States locations

U.S. sites
36
U.S. states
19
U.S. cities
34
Facility City State ZIP Site status
Clinical Site Los Angeles California 90024 —
Clinical Site Northridge California 91325 —
Clinical Site Sacramento California 95815 —
Clinical Site San Diego California 92123 —
Clinical Site Coral Gables Florida 33134 —
Clinical Site Coral Springs Florida 33071 —
Clinical Site Hollywood Florida 33201 —
Clinical Site Margate Florida 33063 —
Clinical Site Miami Florida 33161 —
Clinical Site Tampa Florida 33607 —
Clinical Site Macon Georgia 31217 —
Clinical Site Sandy Springs Georgia 30328 —
Clinical Site West Dundee Illinois 60118 —
Clinical Site Columbus Indiana 47201 —
Clinical Site New Albany Indiana 47150 —
Clinical Site Louisville Kentucky 40241 —
Clinical Site Metairie Louisiana 70006 —
Clinical Site Boston Massachusetts 02116 —
Clinical Site Boston Massachusetts 02215 —
Clinical Site Dearborn Michigan 48126 —
Clinical Site Warren Michigan 48088 —
Clinical Site Las Vegas Nevada 89119 —
Clinical Site New York New York 10012 —
Clinical Site The Bronx New York 10467 —
Clinical Site Boardman Ohio 44512 —
Clinical Site Dayton Ohio 45324 —
Clinical Site Mayfield Heights Ohio 44124 —
Clinical Site Oklahoma City Oklahoma 73118 —
Clinical Site Charleston South Carolina 29425 —
Clinical Site Nashville Tennessee 37215 —
Clinical Site Frisco Texas 75034 —
Clinical Site Houston Texas 77004 —
Clinical Site Houston Texas 77082 —
Clinical Site South Jordan Utah 84095 —
Clinical Site Forest Virginia 24551 —
Clinical Site Mill Creek Washington 98012 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06411899, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 12, 2026 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06411899 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →